Report Store Get Proposal

Home Blog Rare diseases

Rare Diseases

pharma-news-for-gsk-amylyx-ultragenyx

Notizia - Recent Pharma, Healthcare and Biotech Happenings

US FDA Grants Priority Review to Jemperli for dMMR/MSI-H Locally Advanced Rectal Cancer; Amylyx’s Avexitide Achieves Positive Topline Results in Phase 3 LUCIDITY Study; Ultragenyx Marks Major Milestone as FDA Approves GENGLYCOS for GSDIa; Pasatru Receives FDA Approval for Fibrodysplasia Ossificans Progressiva; Merck and Moderna’s Intismeran Autogene Plus KEYTRUDA Delivers Positive Phase 3 Results in Resected Melanoma

GSK’s Jemperli Granted FDA Priority Review for dMMR/MSI-H Locally Advanced Rectal Cancer GSK plc announced that the US Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for priority review of Jemperli (dostarlimab) as a potential treatment for patients with previously untreated stage II or III mismatch repair-deficient (dMMR)/microsatellite instability-high (MSI-H) locally advanced rectal cancer. The FDA has set a PDUFA action date for February 2027. The application is also eligible for expedited assessment under the National Priority Voucher program, which may enable an earlier regulatory decision. Rectal canc...

Explore More...

liquid-biopsy-revolutionary-technique-for-cancer-diagnosis

Liquid Biopsy: The Blood Test That Is Redefining Cancer Diagnosis, Monitoring, And Precision Oncology

systemic-lupus-erythematosus-treatment-landscape

The Evolution of Systemic Lupus Erythematosus Treatment: From Symptom Control to Targeted Therapies

pharma-news-for-gsk-artiva-biogen

GSK Signs Exclusive Collaboration with SBP Group to Strengthen Commercialization of Bepirovirsen in China; Artiva Announces Strong Early AlloNK® Results and FDA Alignment for Pivotal Rheumatoid Arthritis Trial in 2026; FDA Reviews LEQEMBI IQLIK Subcutaneous Starting Dose Under Priority Review Pathway; ParcelBio Announces Programmable mRNA Platform Amid $13M Capital Infusion; Entrada Therapeutics Reports Promising Topline Efficacy and Safety Results for ENTR-601-44 in Duchenne Muscular Dystrophy

top-8-gene-therapies-for-retinitis-pigmentosa-treatment

Top 8 Breakthrough Gene Therapies for Retinitis Pigmentosa Treatment

avlayah-for-hunter-syndrome

Denali’s AVLAYAH Win for Hunter Syndrome Marks Turning Point for Rare Disease Innovation

hypophosphatasia-treatment-market

Exploring Growth Opportunities in the Hypophosphatasia Treatment Market: Navigating the Ultra-rare Disease Landscape

pharma-news-for-sanofi-rhythm-gsk

Sanofi’s Venglustat Gains US Breakthrough Therapy Nod, Boosting Hope for Type 3 Gaucher Disease; Rhythm Pharmaceuticals Expands IMCIVREE Label with FDA Approval in Hypothalamic Obesity; FDA Approves LYNAVOY for Cholestatic Pruritus in PBC Patients; FDA Greenlights J&J/Protagonist’s ICOTYDE, Redefining First-Line Systemic Therapy for Plaque Psoriasis; Novartis Strengthens its Breast Cancer Portfolio Through Acquisition of a Pan-mutant PI3Kα Inhibitor

Science of Epilepsy

Epilepsy: Understanding the Condition Beyond the Seizures

Most Promising Therapies in the Parkinson’s Disease Treatment Market

Most Promising Therapies in the Parkinson’s Disease Treatment Market

pharma-news-for-regeneron-kedrion-crinetics

Regeneron’s EVKEEZA Wins FDA Approval for HoFH in Children as Young as 1 Year; Eli Lilly’s INLURIYO Approved for ER+, HER2-, ESR1-Mutated Advanced Breast Cancer; Janssen’s TREMFYA Secures FDA Nod for Pediatric Plaque Psoriasis and Psoriatic Arthritis; Kedrion Biopharma’s QIVIGY Approved for Primary Humoral Immunodeficiency in Adults; Crinetics Pharma Wins FDA Approval for First Daily Pill, PALSONIFY, for Rare Growth Disorder

Types of Mitochondrial Disorders and the Science Behind Them: A Journey from Dysfunction to Discovery

Types of Mitochondrial Diseases and the Science Behind Them: A Journey from Dysfunction to Discovery

leigh-syndrome-treatment

Leigh Syndrome Treatment: The Ongoing Quest for an Effective Cure

artificial-intelligence-in-healthcare

Most Promising Artificial Intelligence Applications in the Healthcare Segment

pharma-news-for-incyte-abbvie-merck

Incyte’s ZYNYZ Approved as First-Line Treatment for Advanced Anal Cancer; Amneal Gets FDA Nod for BREKIYA for Migraines; FDA Accepts Travere’s sNDA for FILSPARI in FSGS; AbbVie’s EMRELIS Approved for Advanced NSCLC With High c-Met; Merck’s WELIREG Approved for Advanced PPGL in Patients 12+

evolving-prader-willi-syndrome-treatments

Advances in Prader-Willi Syndrome Treatment: New Hope for Patients

mps-i-treatment-pipeline

Mucopolysaccharidosis Type I Treatment Pipeline — 4 Promising Therapies on the Way

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly